Intestinal absorbent improves short-term stool consistency, abdominal pain in IBS-D
Click Here to Manage Email Alerts
SAN DIEGO — Enterosgel, a CE-certified intestinal absorbent, reduced short-term symptoms of stool consistency and abdominal pain among patients with irritable bowel syndrome with diarrhea, according to research.
“The RELIEVE-IBS-D study was set up to investigate the efficacy and safety of Enterosgel for the treatment of irritable bowel syndrome with diarrhea. Enterosgel is a silicone-based hydrogel which binds large molecules in the gut,” Yan Yiannakou, MBChB, consultant neurogastroenterologist and director of the Durham Constipation Service at the University Hospital of North Durham in the United Kingdom, said at Digestive Disease Week 2022. “There's been a randomized control trial in the treatment of acute diarrhea which shows [Enterosgel] has been effective — we were keen to look at it in chronic diarrhea and in terms of IBS.”
In a randomized, placebo-controlled trial, 440 patients with IBS-D, aged 16 to 75 years, received Enterosgel (polymethylsiloxane polyhydrate) or placebo for an 8-week, double-blind treatment phase followed by an 8-week, open-label treatment phase. Patients completed daily questionnaires and recorded symptoms in an e-diary. The primary studied outcome was the percentage of patients who underwent treatment vs. placebo who achieved improved stool consistency and decreased abdominal pain for at least 4 weeks of the 8-week, double-blind treatment phase.
According to study results, Enterosgel led to a significant difference in response rates (OR = 1.89; 95% CI, 1.21-2.97) with individual analysis of stool consistency (OR = 2; 95% CI, 1.31-3.06) and abdominal pain (OR = 1.62; 95% CI, 1.08-2.45) favoring active treatment. Yiannakou noted responder rates of 37.4% in the treatment group vs. 24.3% in the placebo group (OR = 1.95; 95% CI, 1.28-2.99).
“Enterosgel seems to be safe and effective in reducing the main symptoms in IBS-D of bloating, bowel urgency and also some effects on abdominal pain,” Yiannakou concluded. “It seems to also be able to improve the patient’s quality of life.”
Collapse
Yiannakou Y, et al. Abstract 171. Presented at: Digestive Disease Week; May 21-24, 2022; San Diego (hybrid meeting).
Read more about
Click Here to Manage Email Alerts